Department of GI Oncology and Laboratory of Clinical Investigation 4393, Universite Paris-Est Créteil (UPEC), Créteil, France.
Dis Colon Rectum. 2011 Aug;54(8):930-8. doi: 10.1097/DCR.0b013e31821cced0.
Whether patients with stage IV colon cancer and unresectable distant metastases should be managed by primary colectomy followed by chemotherapy or immediate chemotherapy without resection of the primary tumor is still controversial.
This study aimed to evaluate predictive factors associated with survival in patients with stage IV colon cancer and unresectable distant metastases.
This large retrospective multicentric study included 6 academic hospitals.
This study was conducted at 6 Paris University Hospitals (Assistance Publique-Hôpitaux de Paris; Saint Antoine, Henri Mondor, Ambroise Paré, Hôpital Europeen Gorges Pompidou, Bichat, and Avicenne).
Between 1998 and 2007, 208 patients with good performance status and stage IV colon cancer with unresectable distant metastases received chemotherapy, either as initial management or after primary tumor resection.
Survival was estimated by use of the Kaplan-Meier method. Factors associated with survival were tested by means of a log-rank test. Results were expressed as median values with 95% confidence intervals. Factors independently related to survival were tested using a Cox regression model adjusted for a propensity score.
Of the 208 patients, 85 underwent colectomy before chemotherapy, whereas 123 were treated with use of primary chemotherapy with or without biotherapy. At univariate analysis, the following factors were significantly associated with survival: primary colectomy (P = .031), secondary curative surgery (P < .001), well-differentiated primary tumor (P < .001), exclusive liver metastases (P < .027), absence of need for colonic stent (P = .009), and addition of antiangiogenic (P = .001) or anti-epidermal growth factor receptor (P = .013) drugs to chemotherapy. After Cox multivariate analysis and after adjusting for the propensity score, all of these factors, with the exception of two, colonic stent and anti-epidermal growth factor receptor drug, were found to be independently associated with overall survival.
This study was limited by its retrospective nature.
In a selected population of patients with colon cancer and unresectable synchronous distant metastases, immediate colectomy followed by chemotherapy in association with targeted therapy was associated with longer overall survival. This strategy appears to be the most appropriate, especially for those with good performance status, well-differentiated tumors, and synchronous liver metastases only.
对于患有 IV 期结肠癌且远处转移灶不可切除的患者,应选择先行原发肿瘤切除术再进行化疗,还是直接进行化疗而不切除原发肿瘤,目前仍存在争议。
本研究旨在评估与 IV 期结肠癌且远处转移灶不可切除患者生存相关的预测因素。
这是一项大型回顾性多中心研究,共纳入 6 家学术医院。
这项研究在巴黎 6 家公立医院(巴黎公立医院集团;圣安东尼医院、亨利·蒙多医院、阿波斯尔·帕雷医院、欧洲格罗斯蓬皮杜医院、比沙医院和阿维森纳医院)进行。
1998 年至 2007 年间,208 例一般状况良好且患有 IV 期结肠癌且远处转移灶不可切除的患者接受了化疗,化疗方案包括初始治疗和原发肿瘤切除后的治疗。
采用 Kaplan-Meier 法估计生存情况。采用对数秩检验检测与生存相关的因素。结果以中位数及其 95%置信区间表示。使用调整倾向评分的 Cox 回归模型检测与生存相关的独立因素。
在 208 例患者中,85 例行结肠癌切除术,然后再进行化疗,123 例患者直接接受原发肿瘤化疗,其中包括或不包括生物治疗。单因素分析显示,以下因素与生存显著相关:原发肿瘤切除术(P =.031)、二次根治性手术(P <.001)、分化良好的原发肿瘤(P <.001)、单纯肝转移(P <.027)、无需结肠支架(P =.009)、以及化疗中添加抗血管生成药物(P =.001)或抗表皮生长因子受体药物(P =.013)。Cox 多因素分析和倾向评分调整后,除结肠支架和抗表皮生长因子受体药物外,所有这些因素均与总生存独立相关。
本研究存在一定的局限性,因为其为回顾性研究。
在选择的患有不可切除同步远处转移的结肠癌患者人群中,直接进行化疗联合靶向治疗,并在随后进行结肠癌切除术,可显著延长总生存时间。对于一般状况良好、分化良好且仅有同步肝转移的患者,这种治疗策略可能是最恰当的选择。